Janux Therapeutics, Inc.

JANX · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$24-$34-$24-$20
Dep. & Amort.$1$1$1$1
Deferred Tax$0$0$0$0
Stock-Based Comp.$9$11$11$6
Change in WC$7$4-$1-$0
Other Non-Cash-$5-$5-$4-$3
Operating Cash Flow-$13-$24-$17-$17
Investing Activities
PP&E Inv.-$0-$0-$0-$0
Net Acquisitions$0$0$0$0
Inv. Purchases-$118-$93-$371-$24
Inv. Sales/Matur.$126$95$31$58
Other Inv. Act.$0$0$0$0
Investing Cash Flow$8$2-$340$34
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$1$1$378
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$8
Financing Cash Flow$0$1$1$387
Forex Effect$0$0$0$0
Net Chg. in Cash-$4-$21-$357$404
Supplemental Information
Beg. Cash$53$75$431$28
End Cash$49$53$74$431
Free Cash Flow-$13-$24-$17-$17
Janux Therapeutics, Inc. (JANX) Financial Statements & Key Stats | AlphaPilot